FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017077780> ?p ?o ?g. }

• W3017077780 endingPage "109818" @default.
• W3017077780 startingPage "109818" @default.
• W3017077780 abstract "Neuromuscular blocking agents (NMBAs) have revolutionized the field of anesthesiology as they facilitate airway management and ensure optimal surgical conditions. Despite their beneficial and ubiquitous use during surgery, delayed or partial recovery from NMBAs, referred to as residual neuromuscular block (rNMB), is a common clinical problem. While it is well accepted that the antagonist sugammadex, compared to neostigmine, can more rapidly reverse rocuronium-induced NMB regardless of depth of block, the occurrence of rNMB for routinely used combinations of NMBAs with sugammadex or neostigmine has not yet been quantified or evaluated systematically. We conducted a systematic literature review and meta-analysis of randomized controlled trials (RCTs) to quantify and compare the incidence of rNMB [defined as train-of-four ratio (TOFR) <0.9] in patients with moderate and deep neuromuscular block. Methods recommended by Cochrane Collaboration and PRISMA group were followed. A total of 35 RCTs were identified, of which 20 contributed to the meta-analysis. For moderate block, rNMB incidence at 2 min after sugammadex administration was 19.2% (95% CI 0.0–57.8; 122 patients) and declined to 2.8% (95% CI 0.0–16.7; 93 patients) at 6 min post administration. For timepoints 10 to 60 min after administration, rNMB incidence ranged between 0.05% to 2.8%. In contrast, rNMB incidence at 2 min after neostigmine administration was 100% (95% CI 89.9–100; 182 patients) and was 82% (95% CI 71.4–91.2; 93 patients) at 6 min post administration. For timepoints 10 to 60 min after administration, rNMB incidence ranged between 14 and 32%. For deep block, rNMB incidence following sugammadex was essentially reduced to 1% at 15 min after administration. Residual NMB incidence following neostigmine remained at or above 95% for the first 60 min after administration. Overall, based on evidence from 20 RCTs, our results suggest that the combination of rocuronium or vecuronium plus sugammadex is more effective and more rapid in reversing NMB compared with combinations of rocuronium, vecuronium, cisatracurium, or pancuronium plus neostigmine." @default.
• W3017077780 created "2020-04-24" @default.
• W3017077780 creator A5038322806 @default.
• W3017077780 creator A5062912167 @default.
• W3017077780 creator A5067179752 @default.
• W3017077780 creator A5075099161 @default.
• W3017077780 creator A5081547217 @default.
• W3017077780 date "2020-09-01" @default.
• W3017077780 modified "2023-09-26" @default.
• W3017077780 title "Incidence of residual neuromuscular blockade and use of neuromuscular blocking agents with or without antagonists: A systematic review and meta-analysis of randomized controlled trials" @default.
• W3017077780 cites W1801414640 @default.
• W3017077780 cites W1968706118 @default.
• W3017077780 cites W1969390982 @default.
• W3017077780 cites W1983844185 @default.
• W3017077780 cites W1990405213 @default.
• W3017077780 cites W1992566159 @default.
• W3017077780 cites W1999831583 @default.
• W3017077780 cites W2011765774 @default.
• W3017077780 cites W2012036491 @default.
• W3017077780 cites W2035640432 @default.
• W3017077780 cites W2037547757 @default.
• W3017077780 cites W2044173572 @default.
• W3017077780 cites W2047828454 @default.
• W3017077780 cites W2060418932 @default.
• W3017077780 cites W2072286744 @default.
• W3017077780 cites W2082000788 @default.
• W3017077780 cites W2082385062 @default.
• W3017077780 cites W2082753953 @default.
• W3017077780 cites W2096136225 @default.
• W3017077780 cites W2102669415 @default.
• W3017077780 cites W2107328434 @default.
• W3017077780 cites W2117200377 @default.
• W3017077780 cites W2134833483 @default.
• W3017077780 cites W2165664270 @default.
• W3017077780 cites W2166148391 @default.
• W3017077780 cites W2210244516 @default.
• W3017077780 cites W2343631842 @default.
• W3017077780 cites W2512452717 @default.
• W3017077780 cites W2547688835 @default.
• W3017077780 cites W2562035119 @default.
• W3017077780 cites W2613860082 @default.
• W3017077780 cites W2772928337 @default.
• W3017077780 cites W2787864281 @default.
• W3017077780 cites W2919368874 @default.
• W3017077780 cites W2970062481 @default.
• W3017077780 cites W826046956 @default.
• W3017077780 doi "https://doi.org/10.1016/j.jclinane.2020.109818" @default.
• W3017077780 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32304958" @default.
• W3017077780 hasPublicationYear "2020" @default.
• W3017077780 type Work @default.
• W3017077780 sameAs 3017077780 @default.
• W3017077780 citedByCount "25" @default.
• W3017077780 countsByYear W30170777802020 @default.
• W3017077780 countsByYear W30170777802021 @default.
• W3017077780 countsByYear W30170777802022 @default.
• W3017077780 countsByYear W30170777802023 @default.
• W3017077780 crossrefType "journal-article" @default.
• W3017077780 hasAuthorship W3017077780A5038322806 @default.
• W3017077780 hasAuthorship W3017077780A5062912167 @default.
• W3017077780 hasAuthorship W3017077780A5067179752 @default.
• W3017077780 hasAuthorship W3017077780A5075099161 @default.
• W3017077780 hasAuthorship W3017077780A5081547217 @default.
• W3017077780 hasConcept C120665830 @default.
• W3017077780 hasConcept C121332964 @default.
• W3017077780 hasConcept C126322002 @default.
• W3017077780 hasConcept C141071460 @default.
• W3017077780 hasConcept C168563851 @default.
• W3017077780 hasConcept C2776988050 @default.
• W3017077780 hasConcept C2777411258 @default.
• W3017077780 hasConcept C2778560516 @default.
• W3017077780 hasConcept C2778716859 @default.
• W3017077780 hasConcept C2909465803 @default.
• W3017077780 hasConcept C2910841738 @default.
• W3017077780 hasConcept C42219234 @default.
• W3017077780 hasConcept C61511704 @default.
• W3017077780 hasConcept C71924100 @default.
• W3017077780 hasConcept C95190672 @default.
• W3017077780 hasConceptScore W3017077780C120665830 @default.
• W3017077780 hasConceptScore W3017077780C121332964 @default.
• W3017077780 hasConceptScore W3017077780C126322002 @default.
• W3017077780 hasConceptScore W3017077780C141071460 @default.
• W3017077780 hasConceptScore W3017077780C168563851 @default.
• W3017077780 hasConceptScore W3017077780C2776988050 @default.
• W3017077780 hasConceptScore W3017077780C2777411258 @default.
• W3017077780 hasConceptScore W3017077780C2778560516 @default.
• W3017077780 hasConceptScore W3017077780C2778716859 @default.
• W3017077780 hasConceptScore W3017077780C2909465803 @default.
• W3017077780 hasConceptScore W3017077780C2910841738 @default.
• W3017077780 hasConceptScore W3017077780C42219234 @default.
• W3017077780 hasConceptScore W3017077780C61511704 @default.
• W3017077780 hasConceptScore W3017077780C71924100 @default.
• W3017077780 hasConceptScore W3017077780C95190672 @default.
• W3017077780 hasFunder F4320307776 @default.
• W3017077780 hasLocation W30170777801 @default.
• W3017077780 hasLocation W30170777802 @default.
• W3017077780 hasOpenAccess W3017077780 @default.
• W3017077780 hasPrimaryLocation W30170777801 @default.
• W3017077780 hasRelatedWork W16745287 @default.

• next